Epigenomics AG
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Epigenomics AG generated cash of -$4,152,000, which is more than the previous year. Cash used in financing activities reached the amount of $21,619,000 last year. Net change in cash is therefore $19,483,000.
Cash Flow
| 2012 | -10.88M | 954K | -422K |
|---|---|---|---|
| 2013 | -6.50M | -20K | 11.52M |
| 2014 | -7.22M | -874K | 7.60M |
| 2015 | -8.12M | 159K | 9.03M |
| 2016 | -13.28M | -379K | 17.42M |
| 2017 | -9.57M | -548K | 11.49M |
| 2018 | -10.35M | 724K | 13.27M |
| 2019 | -13.50M | 47K | 7.12M |
| 2020 | -9.57M | 3K | 2.98M |
| 2021 | -4.15M | 961K | 21.61M |
EPGNY Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.56M | 10.15M | 16.48M | 12.82M | 11.53M | 7.77M | 6.71M | 7.20M | 2.20M | 12.55M |
Operating activities | ||||||||||
Net income | -2.42M | -11.68M | -17.02M | -12.69M | -10.23M | -11.16M | -8.98M | -8.85M | -7.41M | -12.19M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 419K | 535K | 513K | 308K | 343K | 356K | 668K | 770K | 799K | 923K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2K | 87K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2K | 87K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -52K | 185K | 45K | -66K | -37K | 820K | -324K | -478K | -244K | 252K |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -4.15M | -9.57M | -13.50M | -10.35M | -9.57M | -13.28M | -8.12M | -7.22M | -6.50M | -10.88M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -35K | -21K | -122K | -106K | -583K | -1.26M | -213K | -874K | -20K | -41K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 961K | 3K | 47K | 724K | -548K | -379K | 159K | -874K | -20K | 954K |
Financing activities | ||||||||||
Common Stock Issued | 2.16M | 3.99M | 8.33M | 21.25M | 5.47M | 13.98M | 5M | 4.17M | 9.21M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -748K | -983K | -1.95M | -374K | -729K | -137K | 0 | -555K | -422K |
Repayments of term debt | 0 | 0 | 0 | -6.02M | 0 | 0 | 0 | -423K | -383K | 0 |
Cash used in financing activities | 21.61M | 2.98M | 7.12M | 13.27M | 11.49M | 17.42M | 9.03M | 7.60M | 11.52M | -422K |
Net Change In Cash | 19.48M | -6.58M | -6.33M | 3.66M | 1.29M | 3.75M | 1.06M | -492K | 5.00M | -10.35M |
Cash at end of period | 23.04M | 3.56M | 10.15M | 16.48M | 12.82M | 11.53M | 7.77M | 6.71M | 7.20M | 2.20M |